Results 131 to 140 of about 7,490 (233)

Bruton’s tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia [PDF]

, 2018
AG Evans, B Mizukawa, FM Vega, G Pillinger, H Wu, HP Kuo, HS Kuehn, J Wei, K Bence, L Zaitseva, M Konopleva, MA Ayoub, MY Murray, R Schrage, S Tavor, SA Rushworth, SP Xu, T Oellerich, TL Gu   +18 more
core   +1 more source

Bruton's tyrosine kinase (BTK) [PDF]

Science-Business eXchange, 2010
openaire   +1 more source

Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens. [PDF]

Cureus
Bonsu A.
europepmc   +1 more source

Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies. [PDF]

Sci Rep, 2023
Alrouji M, Benjamin LS, Alhumaydhi FA, Al Abdulmonem W, Baeesa SS, Rehan M, Shahwan M, Shamsi A, Akhtar A.   +8 more
europepmc   +1 more source

Membrane-dependent assembly of Bruton's tyrosine kinase mediated by the Proline-rich region and SH3 domain. [PDF]

Protein Sci
Fenton AD, Chung JK.
europepmc   +1 more source

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors. [PDF]

Intern Med J
Anderson MA, Awan FT, Berkahn L, Crassini K, Lee HP, Marlton P, Mulligan SP, Nolan M, Tam C, Sverdlov AL.   +9 more
europepmc   +1 more source

Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events. [PDF]

Cancer Med
Obeng-Kusi M, De Nigris E, Leng S, Farooqui MZH, Yapici HO, Weimer I, Jiao W, Hyatt HW, Zhang X, Lodaya K, Dingli D.   +10 more
europepmc   +1 more source

FDA-approved small-molecule kinase inhibitors [PDF]

, 2015
Clausen, Mads Hartvig, Nielsen, Thomas E., Wu, Peng   +2 more
core   +1 more source

Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders. [PDF]

ChemMedChem
Almodóvar-Rivera CM, Tandon I, Mudududdla R, Esguerra PN, Lucio-Acero K, Tang W.   +5 more
europepmc   +1 more source

Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy. [PDF]

Ann Med Surg (Lond)
Hujjat SFZ, Chandani HK, Khan MS, Chandani DK, Mahmoud A.   +4 more
europepmc   +1 more source